At www.QualityStocks.Net you can sign up for Quality Stock's Daily Newsletter to find out what Small-Cap and Micro-Cap online Investment Newsletters are interested in, plus hear about the latest news from our clients as well as other publicly traded companies.
We would like to highlight China Medicine Corp. (OTCBB: CHME). The company is a leading pharmaceutical company that discovers and develops medical formulations and distributes over 2,200 pharmaceutical products in China including prescription and over-the-counter drugs, traditional Chinese medicine products, herbs and dietary supplements. The Company distributes the products to wholesale distributors in 28 provinces and to more than 300 hospitals, 500 medicine companies, and 1,788 drug stores throughout China.
In the company’s news today,
China Medicine Corporation (CHME.OB), a developer and distributor of pharmaceuticals and nutritional supplements in China, reported strong second quarter financial results this morning. Revenues increased 40.8% year over year to $11.6 million, compared to $8.3 million in Q2 2007. Net income soared 118.8% to $2.5 million, or 16 cents per share, vs. $1.1 million, or 8 cents per share a year ago. No analysts currently cover the stock.
Sales increased across the entire breadth of the company’s pharmaceutical portfolio. “We are pleased to report strong revenue growth driven by an increase in sales of pharmaceutical products through exclusive nationwide and regional distribution rights, competitive pricing, timely delivery of products and excellent after-sales customer service” commented Mr. Senshan Yang, Chairman and CEO of China Medicine. “Based on our outstanding first half 2008 performance, we feel confident that we will meet our guidance of 25%-35% revenue growth and 30%-35% gross margins for fiscal 2008. In addition, based on our strong second quarter profitability, we expect to exceed our net income guidance of 20%-22% for 2008.”
China Medicine received a patent during the quarter for recombinant aflatoxin-detoxifizyme (rADTZ) in Australia that is valid through January 13, 2025. rADTZ can be used as an additive to remove aflatoxins, potential cancer-causing agents, from animal feed and other food products. The Company has applied for rADTZ patents in 13 other jurisdictions. “The entrance of rADTZ in the animal feed industry is relatively easy since we will only need approval from the Department of Agriculture in China, which is in contrast to entering the food industry, where the process might take years,” said Mr. Yang. “Therefore, our target market is China’s entire feed industry, which is approximately RMB 274.2 billion ($39.8 billion, 1 RMB = $0.145). In the next three years, we hope rADTZ will capture 20% of the animal feed market,” said Mr. Yang.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
